Cipla Tackles Lanreotide Supply Woes, Solidifies India Diabetes Position

 
• By Anju Ghangurde
  
challenges
Tough Q3FY26 for Cipla amid lanreotide supply issues (Shutterstock)

More from Earnings

More from Business